Drug General Information (ID: DDIRNF4TGU)
Drug Name			Peginterferon alfa-2a		Drug Info		Pegloticase		Drug Info
Drug Type		Interferons				Protein/peptide
Therapeutic Class		Antineoplastics				Antihyperuricemic Agents

Mechanism of Peginterferon alfa-2a-Pegloticase Interaction (Severity Level: Moderate)
Attenuated pharmacological effects (Unspecific) Click to Show/Hide Mechanism Graph
Drug Name		Peginterferon alfa-2a				Pegloticase
Mechanism		Reduces pharmacological effects of pegloticase				Pegloticase
Key Mechanism Factor 1
		Factor Name		Pharmacodynamics
		Factor Description		Reduced pharmacological effects leading to insufficient efficacy and/or treatment failure.
Mechanism Description		Attenuated pharmacological effects of  Pegloticase when combined with Peginterferon alfa-2a

Recommended Action
Management		Clinicians should be aware of the potential for diminished effects of other pegylated agents following treatment with pegloticase.

References
1	Product Information. Krystexxa (pegloticase). Savient Pharmaceuticals, East Brunswick, NJ.